Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.
暂无分享,去创建一个
P. Abrams | P. Radziszewski | C. Chapple | M. Small | T. Kuwayama | S. Deacon | T. Masuda | K. Andersson
暂无分享,去创建一个
P. Abrams | P. Radziszewski | C. Chapple | M. Small | T. Kuwayama | S. Deacon | T. Masuda | K. Andersson